NEW YORK (GenomeWeb News) – Amoy Diagnostics today said that it has reached an agreement with OxOnc Development to use Amoy's ROS1 Gene Fusions Detection Kits for a pivotal clinical trial of Pfizer's Xalkori (crizotinib).

Xiamen, China-based Amoy said that it would provide the kits to the labs conducting the study in China, Korea, and Japan. It also will provide technical support for the assay, which uses real-time PCR to detect 14 different fusion products in cDNA derived from tumor tissue or body fluids.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.